In another clinical trial engineered targeting HER-2 CAR NK cells therapy for glioblastoma, 9 patients received treatment with no dose-limiting toxicities, and no patients developed CRS or immune effector cell-associated neurotoxicity syndrome (ICANs). This evidence concerns the gene ERBB2 and glioblastoma.